Specialty Natural Products PCL

The company maintains a strong liquidity position, with a current ratio of 8.83, indicating ample short-term assets to cover liabilities. Its price-to-book ratio of 2.08 and price-to-tangible-book ratio of 2.08 suggest a premium valuation relative to its equity base. However, the company’s net cash position is negative after subtracting total debt, signaling potential liquidity constraints despite its high current ratio. Profitability metrics show a return on equity (ROE) of 12.48% and return on assets (ROA) of 10.92%, both exceeding the typical thresholds for the pharmaceutical industry. Gross profit of 226.09 million THB and operating income of 138.24 million THB reflect strong cost control and operational efficiency. The company’s net income of 111.95 million THB supports its profitability, though the absence of long-term debt suggests a conservative capital structure. The company operates as a single business segment, with all revenue derived from the production and sale of natural extracts and botanical ingredients. Geographically, it is concentrated in Thailand, with manufacturing facilities in Chonburi. There is no disclosed revenue diversification across regions or product lines, which may expose the company to regional economic or regulatory risks. Looking ahead, the company’s revenue outlook for the current fiscal year is stable, with no significant growth or contraction expected. Free cash flow of 41.14 million THB and operating cash flow of 84.15 million THB support its ability to fund operations and reinvest. However, capital expenditures of -14.09 million THB indicate a reduction in investment, which may affect long-term growth potential. Risk factors include medium liquidity risk due to the negative net cash position and the absence of long-term debt, which limits financial flexibility. The company’s dilution risk is low, with no near-term pressure from share issuance or convertible instruments. However, the lack of diversification in revenue sources and geographic exposure may amplify operational risks. Recent filings and transcripts do not disclose material events or strategic shifts. The company’s operations remain focused on its core product lines, with no significant new product launches or market expansions reported in the latest financial data.